APEX HEALTHCARE BHD

KLSE (MYR): AHEALTH (7090)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

2.49

Today's Change

+0.01 (0.40%)

Day's Change

2.48 - 2.50

Trading Volume

62,000

Financial

Show?
Last 10 FY Result
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
Revenue 921,658 913,401 877,742 770,756 698,729 688,786 652,660 620,264 581,269 526,859 499,237 418,451 8.57%
PBT 728,392 436,882 120,355 75,411 70,174 66,334 69,270 56,047 46,294 45,842 45,624 40,615 12.82%
Tax -20,862 -21,402 -19,384 -15,975 -14,163 -13,562 -10,603 -11,559 -11,306 -11,579 -11,647 -10,493 7.05%
NP 707,530 415,480 100,971 59,436 56,011 52,772 58,667 44,488 34,988 34,263 33,977 30,122 14.37%
-
NP to SH 707,530 415,481 100,975 59,418 56,021 52,750 58,581 44,459 34,955 34,236 33,864 30,123 14.37%
-
Tax Rate 2.86% 4.90% 16.11% 21.18% 20.18% 20.45% 15.31% 20.62% 24.42% 25.26% 25.53% 25.84% -
Total Cost 214,128 497,921 776,771 711,320 642,718 636,014 593,993 575,776 546,281 492,596 465,260 388,329 8.00%
-
Net Worth 885,728 885,728 559,642 506,770 468,317 424,170 381,202 343,237 311,587 288,179 260,909 235,264 10.10%
Dividend
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
Div 35,714 43,942 40,313 54,465 21,287 17,438 15,834 14,057 13,470 12,886 11,165 9,373 17.58%
Div Payout % 5.05% 10.58% 39.92% 91.67% 38.00% 33.06% 27.03% 31.62% 38.54% 37.64% 32.97% 31.12% -
Equity
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
Net Worth 885,728 885,728 559,642 506,770 468,317 424,170 381,202 343,237 311,587 288,179 260,909 235,264 10.10%
NOSH 718,028 718,028 477,577 476,249 475,089 471,914 117,546 117,146 117,138 117,146 117,526 93,730 19.81%
Ratio Analysis
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
NP Margin 76.77% 45.49% 11.50% 7.71% 8.02% 7.66% 8.99% 7.17% 6.02% 6.50% 6.81% 7.20% -
ROE 79.88% 46.91% 18.04% 11.72% 11.96% 12.44% 15.37% 12.95% 11.22% 11.88% 12.98% 12.80% -
Per Share
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
RPS 129.03 127.87 185.07 162.74 147.71 146.15 556.44 529.48 496.23 449.75 424.79 446.44 -9.31%
EPS 99.06 58.17 21.29 12.55 11.84 11.19 49.94 37.95 29.84 29.23 28.91 25.63 -2.03%
DPS 5.00 6.15 8.50 11.50 4.50 3.70 13.50 12.00 11.50 11.00 9.50 10.00 -1.78%
NAPS 1.24 1.24 1.18 1.07 0.99 0.90 3.25 2.93 2.66 2.46 2.22 2.51 -8.03%
Adjusted Per Share Value based on latest NOSH - 718,028
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
RPS 128.34 127.19 122.22 107.33 97.30 95.91 90.88 86.37 80.94 73.36 69.52 58.27 8.57%
EPS 98.52 57.86 14.06 8.27 7.80 7.35 8.16 6.19 4.87 4.77 4.72 4.19 14.38%
DPS 4.97 6.12 5.61 7.58 2.96 2.43 2.20 1.96 1.88 1.79 1.55 1.31 17.52%
NAPS 1.2334 1.2334 0.7793 0.7057 0.6521 0.5907 0.5308 0.478 0.4339 0.4013 0.3633 0.3276 10.10%
Price Multiplier on Financial Quarter End Date
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
Date 30/06/23 30/06/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 31/12/14 31/12/13 -
Price 2.37 2.37 3.52 2.69 3.54 2.24 7.80 5.60 4.30 3.60 3.58 4.50 -
P/RPS 1.84 1.85 1.90 1.65 2.40 1.53 1.40 1.06 0.87 0.80 0.84 1.01 7.26%
P/EPS 2.39 4.07 16.53 21.44 29.89 20.01 15.62 14.76 14.41 12.32 12.42 14.00 1.86%
EY 41.79 24.54 6.05 4.66 3.35 5.00 6.40 6.78 6.94 8.12 8.05 7.14 -1.82%
DY 2.11 2.60 2.41 4.28 1.27 1.65 1.73 2.14 2.67 3.06 2.65 2.22 0.91%
P/NAPS 1.91 1.91 2.98 2.51 3.58 2.49 2.40 1.91 1.62 1.46 1.61 1.79 5.82%
Price Multiplier on Announcement Date
AQR T4Q 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 CAGR
Date 23/08/23 23/08/23 22/02/23 23/02/22 25/02/21 19/02/20 28/02/19 22/02/18 23/02/17 25/02/16 25/02/15 26/02/14 -
Price 2.53 2.53 3.39 2.56 3.30 2.41 8.95 4.90 4.65 3.41 3.64 4.40 -
P/RPS 1.96 1.98 1.83 1.57 2.23 1.65 1.61 0.93 0.94 0.76 0.86 0.99 7.06%
P/EPS 2.55 4.35 15.92 20.41 27.87 21.53 17.92 12.91 15.58 11.67 12.63 13.69 1.68%
EY 39.15 22.99 6.28 4.90 3.59 4.64 5.58 7.75 6.42 8.57 7.92 7.30 -1.65%
DY 1.98 2.43 2.51 4.49 1.36 1.54 1.51 2.45 2.47 3.23 2.61 2.27 1.12%
P/NAPS 2.04 2.04 2.87 2.39 3.33 2.68 2.75 1.67 1.75 1.39 1.64 1.75 5.64%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
5 people like this. Showing 50 of 498 comments

Nepo

Hopefully can get some flu drugs sell in China via JV with Shanghai pharma

2022-12-13 17:26

nasgee

wooww LU sonnn fasterr...sure flyy...ang pauu laiii ooo

2022-12-19 12:16

troy88

this one following in the footsteps of Kotra. Solid business even in recession times..

2022-12-20 11:11

troy88

Quality pharma stocks like Kotra and Apex are underrated. Slowly and quietly go up is good..

2022-12-21 09:25

wallstreetrookieNEW

Quality pharma stock but buying now is too late

2022-12-21 09:26

wallstreetrookieNEW

You are just fighting against prop traders at this time. The perfect moment to buy Kotra Industries was 1 year ago December 2021

2022-12-21 09:27

Endgame

Breaking news: China ban medicine and glove export due to high demand to avoid shortage!

2022-12-22 08:52

Nepo

still not bought?
Buy now @RM3.55, you won't regret!

2022-12-29 09:42

Nepo

中国退烧药产量翻4倍 农村缺药依然严重
https://www.chinapress.com.my/?p=3258079

2022-12-30 05:31

troy88

Great QR!

2023-02-23 09:15

wallstreetrookieNEW

Great QR. Apex Healthcare should be in everyone’s portfolio now

2023-02-23 09:58

troy88

Underrated stock. Pharma business is growing and recession proof!

2023-02-23 10:58

wallstreetrookieNEW

Public Bank hold rating. Which means this stock will pump up at least 20%. Still have meat on the table

2023-02-23 12:54

Nepo

@wall, mind sharing with us why Public Bank suggest hold but still have meat available..

2023-02-23 13:08

moven00

The trend and behavior of AHealth for me resembles of Public Bank. Create value to shareholders in long term.

2023-02-24 14:50

donald770

Good!!!

2023-03-25 19:01

troy88

wow, broke RM4 on uptrend. Too bad took profit a bit early 3.90. Apex stock has outperformed Kotra this year by a country mile..

2023-03-29 09:58

Integrity. Intelligent. Industrious. 3iii (iiinvestsmart)$€£¥

Security LastPr PE DY% Divcts ROE ttm-marg
AHEALTH (Pharmaceuticals) 4.09 19.35 2.1 8.5 17.92 11.5

2023-03-30 16:14

Nepo

In the light of these results, the Board has proposed
an increased final single-tier dividend of 3.5 sen per
share as well as a special dividend of 2.0 sen per share
in respect of financial year ended 31st December 2022
for shareholders’ approval at the forthcoming Annual
General Meeting (‘AGM’) scheduled in May 2023. In all,
total dividends paid and payable by the Group in respect
of financial year 2022 is 8.5 sen per ordinary share,
amounting to 40.2% of Group profit after tax.

2023-04-27 10:21

Nepo

The Board is also proposing a 1 for 2 bonus issue of
new shares, without capitalization of retained earnings,
to reward shareholders for their continuous support
and loyalty. We trust the bonus issue will help improve
trading liquidity and enlarge our base of shareholders

2023-04-27 10:21

Nepo

2022 marks the 60th anniversary of the founding of the
Group in 1962. From a retail pharmacy in Melaka, AHB has
grown to a public company with a market capitalization
of RM 1.68 billion1
with operations and commercial
presence in 20 territories today. An initial investment in
1,000 shares at the time of AHB’s Initial Public Offering
(‘IPO’) in year 2000 would be approximately 9,375 shares
if held till today, after 4 bonus issues2
. At RM 1.50 per
share at IPO, the value of that investment would be RM
33,000 today, based on the closing share price of RM
3.52 on 31st December 2022. This is a compound annual
growth rate in value of 15.09% in each of the last 22
years and made possible through the support of every
stakeholder, foremost our people, our customers, and
our shareholders

2023-04-27 10:22

Nepo

if this growth can persist, buy Ahealth let them runn our investment.
At 15% compound interest is very good already
not need hassle to buy what stocks to invest

2023-04-27 10:24

moven00

AHealth Power….

2023-04-27 23:24

Nepo

If you have choice, which way you would prefer:
1). Kill a goose and collect all the gold eggs one off worth around RM 350 million. If you put in FD @3.25%, you get RM 10 million interest.

2). You continue to rear the goose and collect aboutRM 30 million gold eggs every year with compound increment of around 10% additional eggs. You have the risk of goose being die off anytime though not possible in a foresable future

2023-04-29 22:15

pang72

Why need to sale the good profit company?

2023-05-02 22:16

Nepo

https://www.klsescreener.com/v2/news/view/1147527

2023-05-02 22:47

Nepo

omg die kaw kaw, sb pls help..

2023-05-03 15:32

stockraider

What die leh ???

Quickly sell & take profit loh!

2023-05-03 15:58

wallstreetrookieNEW

Healthcare is the only sector that will perform well alongside hard assets (gold/commodities) in an era of stagflation

2023-05-05 10:48

wallstreetrookieNEW

Amazing balance sheet and cash flow. HOLD

2023-05-05 10:48

Nepo

Top up@RM 3.93
Hopefully not become water fish

2023-05-10 15:24

Nepo

Ahealth vs Kotra, at present price, which one has more potential?

2023-05-20 09:14

Nepo

Cum dividend price RM 3.99
Dividend RM 0.06
Wondering ex dividend price can stabilise at how much?
Today is 1 Jun 23
Happy Gawai

2023-06-01 08:20

Nepo

Ahealth RM 3.93
TIMEDOTCOM RM 5.32
WCE RM 0.40
Padini RM 3.70
Pchem RM 6.52

Which counter has the best potential after 5 years?
Anyone veteran can tell me..?

Dated today 5 Jun 23
Five years later, which counters mentioned above has the best potential or best ROE?

2023-06-05 17:16

Nepo

Any clue? Dr Kee

2023-06-05 22:07

Nepo

After Ex-Bonus, price stabilize at RM 2.60 which means any price below RM 2.50 is worth to top-up

2023-06-08 11:41

Nepo

feeling pleasure today because no one comments here. I am the one who dominate this place
it likes your are king in this place right now

2023-06-08 11:42

Nepo

yes, i already topped up
it is one of the counter in klse i long term buy in.
i trust this mgt and hoping Dr Kee continues keep it upp..

2023-06-10 09:38

hw0706

best is below RM2.00

2023-06-12 19:47

Nepo

waiting at RM 2.20
This is a money game. Only those have extra fund can survive..sigh..

2023-06-15 09:37

Nepo

RM 2.36 = cum div & cum bonus RM 3.60
accumulating, anyone follow me?

2023-06-19 09:14

Nepo

This the only counter in klse i m willing to borrow money and buy more..

2023-06-19 09:20

Nepo

The best time to collect this stock is when it is weak and now is the best chance to slowly accumulating this stock.

2023-06-23 11:50

Nepo

one day this stock will prove my judgement...

2023-06-23 14:50

winner168

With yesterday's volume and candle, seems QR would be good?🤔

1 month ago

troy88

Well done!

1 month ago

BareFootInvestor

keep in view

1 month ago

moven00

Only way to buy AHealth is when there is blood all over here @ selldown with fundamental intact. Normal day can forget about it.

1 month ago

moven00

Singapore Kia very kedekut one lo. Then we also have to remember there are sharks @ Fund Managers all waiting too. But in long term this singapore Kia create value to himself by giving bonus issue la. Retailer who hold long long indirectly benefited. That’s the characteristic of AHealth. Other than that don’t even think of them giving you generous dividend or Premium Buffet in AGM. Probably ask yourself to buy your own mineral water in their AGM. LOL

1 month ago

Nepo


Commentary
a Prospects



The Group’s core manufacturing and distribution businesses continue to perform well in the second quarter of 2023, driven by the Group’s commitment to sales
growth, new product development, brand management, customer service and operational efficiency. Demand for pharmaceuticals, consumer healthcare
products and medical devices remained firm in the first half of 2023, supported by the sales momentum from 2022.
Business prospects for the Group’s Penang-based associate SAG remain unchanged from the first quarter. A portion of the proceeds received by SAG from the
divestment of equity in SA to Quadria Capital has been paid to shareholders as dividends and the Group is actively evaluating opportunities to invest dividends
received in new business projects. Details will be announced should these materialize.
For the second half of 2023, the Group expects the business environment to be more challenging as economic growth in our key markets slows. However, the
Group is confident that its proven and well-placed fundamentals, business development strategies, as well as new opportunities in consumer health, halal
certification and international markets are expected to support performance. Barring any unforeseen circumstances, the Group expects to deliver a satisfactory
result in 2023 and is confident that its longer-term growth prospects remain positive.

1 month ago

Post a Comment